GlobalPharmaceutical Survey 2013-2014: Market Trends, Marketing Spend and SalesStrategies in the Global Pharmaceutical Industry is a new report by ICD Research that analyzes
how pharmaceutical industry companies' media spend, marketing and sales
strategies and practices, and business planning are set to change in 2013-2014.
Additionally, this report also presents comparative analysis between four years
of survey results (wherever applicable). This report provides the current size
of the marketing and advertising budgets of global pharmaceutical industry
suppliers and how spending by global pharmaceutical industry suppliers will
change, providing an insight into global marketing behaviour. In addition, the
report identifies future growth of global pharmaceutical industry buyers and
suppliers and MandA activity. This report not only grants access to the
opinions and strategies of business decision makers and competitors, but also
examines their actions surrounding business priorities. The report also
provides access to information categorized by region, company type and sizes.”
Introduction and
Landscape
Why was the report
written?
This report is the
result of an extensive survey drawn from ICD Research's exclusive panel of
leading global pharmaceutical industry executives. The report provides data and
analysis on global pharmaceutical industry suppliers' media spend, marketing
and sales strategies, and practices and business planning within the global
pharmaceutical industry. This report includes key topics such as media channel
spending outlooks, media budgets, marketing agency selection criteria, business
challenges, and sales tactics of leading suppliers within the global
pharmaceutical industry. The report also identifies global pharmaceutical
industry buyers' and suppliers' future growth, MandA and investment
expectations. Most secondary research reports are based on general industry
drivers and do not understand the industry executives' attitude and changing
behaviours, creating a gap in presenting the business outlook of the industry.
In an effort to bridge this gap, ICD Research created this primary-research
based report by gathering the opinions of multiple stake holders in the
value-chain of the global pharmaceutical industry
What is the current
market landscape and what is changing?
The average size of
the annual marketing budget of global pharmaceutical industry supplier
respondents stood at US$4.2 million in 2012, a figure that decreased to US$2.6
million in 2013.
What are the key
drivers behind recent market changes?
In the process of
choosing marketing agencies, the 'ability to target specific audience niches',
'strategic and tactical consulting', and the 'ability to generate leads or
setup customer meetings' are considered the most important factors by global
pharmaceutical industry suppliers.
What makes this
report unique and essential to read?
This report is the
result of an extensive survey drawn from ICD Research's exclusive panel of
leading pharmaceutical industry companies. This report provides the reader with
a definitive analysis of the industry outlook and explores how opportunities
and demand are set to change in 2013-2014. Additionally, this report also
presents comparative analysis between four years of survey results (wherever
applicable). Furthermore, the report reveals the current size of pharmaceutical
industry suppliers' marketing and advertising budgets and how expenditure by
industry suppliers will change, providing insight into global marketing
behavior. This report identifies the key marketing aims of organizations and
the sales strategies companies will adopt in order to adapt to market
conditions in 2013. Additionally, this chapter also aims to identify key
amendments to marketing agencies that aid business generation, respondents'
criteria for marketing agency selection, and attitudes towards marketing and
sales.
Companies
covered in this market research report
are-
Eli Lilly, Avid Radiopharmaceuticals,
Roche, Johnson and Johnson, Mozambica, Mozambican Medicines Company, Mylan
Pharmaceuticals Private Limited, AstraZeneca, MedImmune, WuXi AppTec, Pfizer,
Bristol-Myers, Sanofi, Astellas Pharma, Sanwa Kagaku Kenkyusho, STS Health,
Avita Medical, Guppy Plastics, Mylan Laboratories, TiGenix, DiaMedica, Suzhou
Pharma, Arrowhead Research, Shire, biOasis Technologies, UCB, Immunovative
Therapies, Lonza, UBICHEM Group, UBICHEM Pharma, BASF, Equateq, SAFC,
Sigma-Aldrich, Semantelli, Novartis, UMN Pharma, Catalent Pharma Solutions,
Sihuan Pharmaceutical Holdings, Dendreon Corporation, DBV Technologies,
GENEWIZ, Bayer HealthCare Pharmaceuticals, Vitapath, Nextrials, LGC, Quotient
Bioresearch, Bio-Rad Laboratories, AbD Serotec, MorphoSys AG, NextWave
Pharmaceuticals, OPKO Health, DiscoveRx, BioSeek, Poxel, Nuron Biotech, Takeda,
Takeda America Holdings, LigoCyte Pharmaceuticals, Block Engineering, Lexmark
International, Acuo Technologies, Zhejiang Hisun Pharmaceuticals, Abbot, Essex
Woodlands, Novavax, CPL Biologicals, Dr. Reddy's Laboratories, Debiopharm
Group, Omkar Speciality Chemicals, Thermo Fisher Scientific, Bosch Packaging
Technology, Amgen, TG Therapeutics, Ildong Pharmaceutical, Teva Pharmaceutical
Industries, Handok Pharmaceuticals, Aptuit, Biophytis, Boehringer Ingelheim,
Super Supplements, Mercent, Amazon, eBay, ANTS, TetraPak, Darbox, Visiopharm
Inquire
about this report:
No comments:
Post a Comment
Note: only a member of this blog may post a comment.